Collaboration Track Record Glycotope has a history of oncology partnerships with major players (Daiichi Sankyo, LegoChem), signaling receptiveness to co-development and licensing deals for ADCs and other antibody modalities.

GlycoTarget Niche The proprietary GlycoTargets provide tumor-specific antibody opportunities across multiple modalities (naked antibodies, ADCs, bispecifics, cellular therapies, and fusion proteins), enabling diverse licensing options.

Strategic Pivot Recent asset sale to PentixaPharm and the spin-out of services in 2022 point to a sharpened focus on discovery and development pipelines, presenting collaboration or licensing avenues for their target discovery platform.

Financial Scale Fit With a small team and modest revenue, Glycotope is well-suited for milestone-driven partnerships and risk-sharing deals that align with a larger partner's development and commercialization timelines.

Global Positioning Located in Berlin with a track record of pharma collaborations, Glycotope offers European access and potential for international co-development, licensing, or contract research services in glyco-targeted immuno-oncology.